重组胶原蛋白“第一股”有点意外。 近日，巨子生物（2367.HK）发布的中报显示，上半年公司实现营收29.18亿元，同比下降6.3%；归母净利润9.4亿元，同比下跌20.5%。 这是该公司上市以来，首份营收与净利润“双降”的中期“成绩单”，令市场和投资者大跌眼镜。 一年前，巨子生物凭借“重组胶原蛋白”概念，市值一度逼近千亿港元。如今，在经历品牌信任危机后其市值已缩水至约260亿港元，较高点...
Source Link重组胶原蛋白“第一股”有点意外。 近日，巨子生物（2367.HK）发布的中报显示，上半年公司实现营收29.18亿元，同比下降6.3%；归母净利润9.4亿元，同比下跌20.5%。 这是该公司上市以来，首份营收与净利润“双降”的中期“成绩单”，令市场和投资者大跌眼镜。 一年前，巨子生物凭借“重组胶原蛋白”概念，市值一度逼近千亿港元。如今，在经历品牌信任危机后其市值已缩水至约260亿港元，较高点...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.